Investigational drug · Phase 2
ALMB-0168
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Advanced Solid Tumors With Bone Only Metastasis.
Phase 2Last checked: Nov 20, 2026Latest source record: May 16, 2024 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
2
Any phase or sponsor naming "ALMB-0168"
First trial start
2024
May 2024
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "ALMB-0168", any sponsor or status.
Conditions studied
As listed on its trial records.
- Advanced Solid Tumors With Bone Only Metastasis
Approved drugs for the same conditions: Oncology
Largest trials
Live from ClinicalTrials.gov: studies naming "ALMB-0168" as an intervention, largest first.
- A Study to Evaluate the Safety and Efficacy of ALMB-0168 in Patients With OsteosarcomaStatus unknown
AlaMab Therapeutics (Shanghai) Inc.Industry
NCT04886765 · 238 participants (planned) · Start May 2021 · Primary completion Nov 2023
Drug: ALMB-0168 · For: Osteosarcoma
- A Study to Evaluate the Efficacy of ALMB-0168 in Solid Tumor Patients With Bone Metastatic Whose Prior Standard Treatment Have FailedNot yet recruiting
AlaMab Therapeutics (Shanghai) Inc.Industry
NCT06416358 · 144 participants (planned) · Start May 2024 · Primary completion Jun 2026
Drug: ALMB-0168 · For: Advanced Solid Tumors With Bone Only Metastasis
Newest research
PubMed records naming it or its code names, newest first.
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.